Menu Close

Trending

Bayer grabs Chinese okay for CKD therapy Kerendia
Novartis eyes earlier use of PD-1 drug in oesophageal cancer
A 3-step guide to addressing difficult issues and creating mutual solutions
AZ takes aim at BMS’ lead in neoadjuvant NSCLC
Blueprint cashes in on the past to build its future

The Institute of Cancer Research

Cancer research faces uncertain post-COVID landscape

Deep Dive/ Oncology/ Views & Analysis/ Views and analysis

Cancer research faces uncertain post-COVID landscape

, , , , , , 0 Comment

There’s a bright future ahead for cancer research in the UK, but only if the government is able

X
Cancer research faces uncertain post-COVID landscape
https://pharmaphorum.com/views-analysis-oncology/cancer-research-faces-uncertain-post-covid-landscape/
Zytiga_pack

News/ News/ Oncology

NICE’s second Zytiga rejection ‘shows need for flexible pricing models’

, , , , , 0 Comment

NICE has stuck with its original decision to reject NHS funding for Johnson & Johnson’s Zytiga as a

X
NICE’s second Zytiga rejection ‘shows need for flexible pricing models’
https://pharmaphorum.com/news/nice-second-zytiga-rejection-shows-need-for-flexible-pricing-models/

Login

CONTINUE TO SITE >
X
Close in 10 seconds